Brief: Galecto Inc Says First Patient Enrolled In Phase 2 Trial Of GB1211 In Combination With Atezolizumab For First-Line Treatment Of NSCLC

Damora Therapeutics

16/06/2022 13:24

June 16 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO INC - FIRST PATIENT ENROLLED IN PHASE 2 TRIAL OF
GB1211
IN COMBINATION WITH ATEZOLIZUMAB FOR FIRST-LINE TREATMENT OF
NSCLC

Source text for Eikon:  ID:nGNX4FNG3s 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))